AMGN 10-Q Quarterly Reports

Amgen Inc. reported strong financial performance for the third quarter and first nine months of 2025, with total revenues increasing by 12% and 11% year-over-year, respectively, driven primarily by robust volume growth across its key products. Net income saw significant increases, up 14% for the quarter and a substantial 84% for the nine-month period, leading to a corresponding surge in diluted Earnings Per Share (EPS). The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues. Strategic investments in late-stage clinical programs continue, supported by strong operational cash flow generation. The company's balance sheet remains solid, though cash and cash equivalents decreased slightly from year-end 2024, largely due to significant debt repayment and dividend payments. Amgen continues to manage its debt effectively, reducing its overall debt principal. The company also highlighted ongoing legal matters, particularly the significant U.S. Tax Court case, which, while expected to be resolved no earlier than the second half of 2026, continues to be a point of attention. Despite potential regulatory headwinds and ongoing litigation, Amgen's operational performance and strategic investments indicate a positive outlook for future growth.

Amgen Inc. reported robust top-line growth for the second quarter and first half of 2025, with total revenues increasing by 9% and 10% respectively compared to the prior year periods. This growth was primarily driven by strong volume increases across key products, notably Repatha, EVENITY, BLINCYTO, and TEZSPIRE, which collectively offset modest net selling price declines. The company demonstrated significant profitability improvements, with net income soaring by 92% and 92% for the respective periods, and diluted EPS more than doubling year-over-year. This performance was supported by improved cost of sales as a percentage of revenue and well-managed selling, general, and administrative expenses, although R&D investments saw an increase. Despite the strong operational performance, investors should note the ongoing legal challenges, particularly the significant tax dispute with the IRS concerning past tax years, which continues through the judicial process. The company also faces ongoing patent litigations related to its key products like Repatha and Prolia/XGEVA, with several new biosimilar infringement lawsuits filed. While Amgen has a strong liquidity position with substantial cash and cash equivalents, its balance sheet reflects a notable decrease in cash from the prior year-end, largely due to significant debt repayments and dividend distributions. The company reiterated its commitment to capital allocation through debt reduction, dividends, and stock repurchases.

Amgen Inc. reported a significant turnaround in the first quarter of 2025, with net income swinging from a loss of $113 million in Q1 2024 to a profit of $1.73 billion in Q1 2025. This substantial improvement was driven by a robust increase in total revenues, which grew by 9% year-over-year to $8.15 billion, primarily fueled by an 11% rise in product sales to $7.87 billion. The company's operating income also saw a healthy increase of 19% to $1.18 billion, reflecting effective cost management despite a notable $800 million impairment charge related to Otezla. The balance sheet shows a decrease in cash and cash equivalents to $8.81 billion from $11.97 billion, alongside a reduction in total debt. The company continues to prioritize shareholder returns, declaring a quarterly dividend of $2.38 per share, underscoring its commitment to financial health and shareholder value. Investors should note the ongoing legal proceedings, particularly the significant U.S. tax litigation, which remains a key area of focus, although a decision is not expected until the second half of 2026.

Amgen Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $8.5 billion, up 23% year-over-year. This growth was primarily driven by a substantial 24% increase in total product sales, largely attributable to the successful integration of products acquired from Horizon Therapeutics. Key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE showed strong volume growth. Despite the revenue surge, net income saw a notable 64% increase to $2.83 billion, with diluted EPS rising to $5.22, reflecting improved operational efficiency and strategic asset contributions. However, operating expenses also grew significantly, up 32% in the quarter, largely due to higher amortization related to acquisition-related assets and increased R&D and SG&A spending. The company also reported a decrease in cash and cash equivalents to $9.0 billion from $10.9 billion at the end of the prior year, primarily due to debt repayments and dividend payments, though the company maintains ample liquidity. Investors should note the ongoing substantial legal and tax contingencies, particularly the IRS tax dispute, which continue to pose potential risks despite Amgen's belief in its strong legal standing.

Amgen Inc. reported a notable increase in total revenues for the second quarter of 2024, reaching $8.4 billion, a 20% rise compared to the same period in the prior year. This growth was primarily driven by a significant 20% increase in product sales, largely attributable to the successful integration of Horizon Therapeutics and strong volume growth across key products. Despite the top-line expansion, operating income and net income experienced a decline due to a substantial increase in operating expenses, primarily driven by higher amortization related to the Horizon acquisition and increased R&D and SG&A expenses. Diluted EPS saw a corresponding decrease. The company's balance sheet shows a decrease in cash and cash equivalents to $9.3 billion from $10.9 billion at the end of 2023, alongside a reduction in total assets and stockholders' equity. Long-term debt also decreased. Amgen continued its commitment to capital allocation through dividend payments, though no shares were repurchased during the first half of 2024. The company remains focused on investing in innovation and managing its debt.

Amgen Inc. reported a net loss of $113 million, or $(0.21) per share, for the first quarter of 2024, a significant shift from the $2.84 billion net income reported in the same period last year. This change was largely attributed to substantial non-cash charges, including unrealized losses on strategic equity investments and increased amortization and acquisition-related expenses stemming from the recent Horizon Therapeutics acquisition. Despite the net loss, total revenues grew by 22% year-over-year to $7.45 billion, driven by a 22% increase in product sales to $7.12 billion. The growth in product sales was primarily fueled by volume increases, with significant contributions from newly acquired Horizon products like TEPEZZA and KRYSTEXXA. Operationally, the company saw robust growth in key products such as Repatha (33% increase) and TEZSPIRE (80% increase), alongside contributions from the newly acquired Horizon portfolio. However, operating expenses surged by 54%, largely due to the impact of the Horizon acquisition, including higher amortization and acquisition-related costs, alongside increased R&D and SG&A expenses. The company also continues to navigate complex legal and tax matters, including an ongoing IRS tax dispute with potentially significant financial implications. Amgen's balance sheet remains solid, with substantial cash and cash equivalents, though debt levels remain elevated following the acquisition.

Amgen Inc. reported total revenues of $6.9 billion for the third quarter of 2023, a 4% increase compared to the same period last year, driven by a 5% rise in product sales to $6.5 billion. For the nine-month period, total revenues grew by 3% to $19.99 billion. Net income for the third quarter was $1.73 billion, a decrease of 19% year-over-year, resulting in diluted EPS of $3.22. However, for the nine-month period, net income surged by 21% to $5.95 billion, with diluted EPS of $11.06, demonstrating strong performance over the year-to-date. A significant event during the quarter was the completion of the acquisition of Horizon Therapeutics plc on October 6, 2023, for approximately $27.8 billion. This strategic move is expected to bolster Amgen's inflammation portfolio with key treatments for rare inflammatory diseases. The company also made progress in its pipeline, announcing positive Phase 2 data for tarlatamab in small cell lung cancer and positive Phase 3 data for LUMAKRAS/LUMYKRAS in colorectal cancer.

Amgen Inc. reported solid financial results for the second quarter and first half of 2023, demonstrating revenue growth driven by key products like Prolia and Repatha. Total revenues for the quarter rose 6% to $6.99 billion, with product sales increasing by 6% to $6.68 billion. For the first six months, total revenues grew 2% to $13.09 billion, and product sales were up 4% to $12.53 billion. Net income for the quarter was $1.38 billion, a 5% increase year-over-year, translating to diluted EPS of $2.57, up 5%. The first half of the year saw a substantial 51% increase in net income to $4.22 billion, with diluted EPS soaring 53% to $7.86. This strong performance was bolstered by a significant increase in cash from operations and strategic debt issuances related to the proposed acquisition of Horizon Therapeutics, alongside a notable increase in long-term debt. The company continues to navigate potential regulatory challenges, particularly the FTC's lawsuit seeking to block the Horizon acquisition, with a preliminary injunction hearing scheduled. Amgen also remains engaged in ongoing patent litigation and tax disputes, though the company expresses confidence in its legal positions and financial resilience.

Amgen Inc. reported total revenues of $6.105 billion for the first quarter of 2023, a slight decrease from $6.238 billion in the same period of 2022. Despite the revenue dip, net income saw a significant increase, soaring to $2.841 billion ($5.28 diluted EPS) from $1.476 billion ($2.68 diluted EPS) in the prior year. This substantial earnings growth was largely driven by a substantial "Other income (expense), net" of $2.064 billion, primarily attributed to a significant unrealized gain from revaluing their investment in BeiGene. The company's strategic debt issuances totaling $24.0 billion in March 2023 were to finance the proposed acquisition of Horizon Therapeutics, which remains subject to regulatory review. Product sales showed modest growth of 2% to $5.846 billion, bolstered by strong performances from Prolia, Repatha, Nplate, and EVENITY. However, Enbrel and Otezla experienced declines. Operating expenses increased by 12% due to higher costs of sales, R&D investments, and expenses related to a restructuring plan. The company ended the quarter with a robust cash position of $31.6 billion, with a significant portion earmarked for the Horizon acquisition.

Amgen Inc. reported solid financial results for the third quarter and first nine months of 2022, demonstrating resilience despite a challenging macroeconomic environment. Total revenues for the nine months increased by 2% year-over-year to $19.48 billion, driven by product sales growth and increased other revenues. Net income also saw a significant increase of 24% for the same period, reaching $4.94 billion, with diluted Earnings Per Share (EPS) rising to $9.11. The company's operating income showed substantial growth, up 38% for the nine-month period, reflecting effective cost management and operational efficiency. The company continued its strategic capital allocation through robust share repurchases and dividend payments, underscoring its commitment to returning value to shareholders. Amgen also made significant progress on its pipeline, highlighted by positive trial results for LUMAKRAS/LUMYKRAS. The recent acquisition of ChemoCentryx, Inc. for approximately $3.7 billion is expected to further enhance its therapeutic offerings in autoimmune diseases, inflammatory disorders, and cancer, positioning the company for future growth.

Amgen Inc. reported solid financial results for the second quarter and first half of 2022. Total revenues grew modestly, driven by a 3% increase in product sales for both the quarter and the six-month period. This growth was primarily fueled by strong performance in key products like Prolia, Otezla, XGEVA, Repatha, and KYPROLIS, which experienced double-digit percentage increases in sales. Operating income saw a substantial increase of 58% for the six months ended June 30, 2022, largely due to the absence of a significant acquired in-process research and development (IPR&D) charge recorded in the prior year from the Five Prime acquisition. Diluted Earnings Per Share (EPS) also showed significant improvement, rising 41% for the six months. The company's balance sheet remains robust, though cash and cash equivalents decreased compared to the prior year-end, partly due to significant share repurchases. Amgen continued its commitment to returning capital to shareholders, repurchasing approximately $6.4 billion in stock and paying dividends during the first six months of the year. The company also announced a proposed acquisition of ChemoCentryx for approximately $4.0 billion, indicating a continued strategy of growth through business development. Despite positive operational performance, investors should note the ongoing significant U.S. Tax Court litigation concerning tax years 2010-2015, which could result in substantial additional tax liabilities if the IRS's position prevails. While Amgen believes its tax accruals are appropriate, this remains a notable risk factor.

Amgen Inc. reported total revenues of $6.238 billion for the first quarter of 2022, an increase of 6% from $5.901 billion in the prior year period. This growth was primarily driven by a 64% surge in "Other revenues," largely attributable to COVID-19 antibody material sales, and a 2% increase in product sales to $5.731 billion. Despite the top-line growth, net income decreased by 10% to $1.476 billion, or $2.68 per diluted share, compared to $1.646 billion, or $2.83 per diluted share, in Q1 2021. The decrease in net income was influenced by higher interest expenses and net losses on strategic equity investments. Key operational highlights include continued growth in key products like Prolia, XGEVA, Repatha, and Kyprolis, which saw double-digit percentage increases in sales. However, Enbrel and Neulasta experienced sales declines, with Neulasta significantly impacted by biosimilar competition. The company also repurchased a substantial amount of its common stock, totaling $6.4 billion in the first quarter, and declared a quarterly dividend of $1.94 per share. Significant legal matters, particularly a tax dispute with the IRS, continue to be a point of attention, with the company contesting substantial proposed tax liabilities. Investors should note the strong revenue growth driven by non-core product sales, alongside a decline in profitability. While key growth products demonstrate positive momentum, the impact of biosimilar competition on established products like Neulasta remains a significant factor. The company's aggressive capital return program, including substantial stock repurchases, and the ongoing significant tax litigation are critical factors for investors to monitor.

Amgen Inc. reported total revenues of $6.71 billion for the third quarter of 2021, a 4% increase compared to the same period in the prior year. This growth was driven by a 19% increase in Rest of World (ROW) product sales and a 21% increase in other revenues, largely attributed to sales of COVID-19 antibody material. However, net income decreased by 7% year-over-year to $1.88 billion, and diluted earnings per share (EPS) declined by 3% to $3.31. The nine-month period ending September 30, 2021, showed a 2% increase in total revenues to $19.13 billion, but a significant 29% drop in net income to $3.99 billion and a 27% decrease in diluted EPS to $6.93. This decline in profitability was significantly impacted by higher operating expenses, including $1.5 billion in acquired in-process research and development related to the Five Prime acquisition and a $400 million upfront payment for a licensing agreement with Kyowa Kirin. The company also faces ongoing significant legal challenges related to U.S. tax matters, with a potential tax liability of approximately $3.6 billion, plus interest, which could materially impact future financial statements. Amgen continues to return capital to shareholders through dividends and stock repurchases, with approximately $2.9 billion remaining under its stock repurchase program as of September 30, 2021. Subsequent to the quarter, the company announced an additional $4.5 billion authorization for repurchases. The company also completed the acquisition of Teneobio, Inc. for an upfront payment of $900 million, plus potential future milestone payments, to expand its pipeline in antibody therapeutics.

Amgen Inc. reported total revenues of $6.53 billion for the second quarter of 2021, a 5% increase compared to the same period in the prior year, primarily driven by other revenues and growth in certain key products. However, net income and diluted Earnings Per Share (EPS) saw a significant decline of 74% and 73% respectively, to $464 million and $0.81 per share. This decrease is largely attributable to a substantial increase in operating expenses, notably $1.5 billion in acquired in-process research and development (IPR&D) related to the Five Prime Therapeutics acquisition. Despite the year-over-year dip in profitability for the quarter, the company demonstrated strong performance in specific product areas such as Prolia®, Repatha®, and XGEVA®, which showed double-digit percentage increases in sales. The company also continues to return capital to shareholders through dividends and an active stock repurchase program. Looking ahead, Amgen faces ongoing challenges including biosimilar competition for key drugs like Enbrel® and Neulasta®, and significant ongoing U.S. tax litigation with the IRS that could materially impact future financial results.

Amgen Inc. reported total revenues of $5.901 billion for the first quarter of 2021, a decrease of 4% compared to $6.161 billion in the prior year period. This decline was primarily driven by a 5% decrease in total product sales, largely due to lower net selling prices for certain products, particularly Enbrel and Neulasta, and the ongoing impact of the COVID-19 pandemic on patient access and diagnoses. Despite the revenue dip, operating expenses saw a slight decrease of 1%, and net income stood at $1.646 billion, resulting in diluted Earnings Per Share (EPS) of $2.83, down from $3.07 in the prior year. The company demonstrated its commitment to returning capital to shareholders by repurchasing $865 million of common stock and declaring a quarterly dividend of $1.76 per share. Cash flow from operations remained robust at $2.104 billion. Amgen also advanced its strategic growth initiatives, notably completing the acquisition of Five Prime Therapeutics for approximately $1.9 billion to bolster its oncology pipeline. The company continues to navigate the uncertainties of the COVID-19 pandemic, which has impacted patient interactions and product demand, but believes its financial position remains adequate to meet its obligations and pursue future opportunities.

Amgen Inc. reported solid revenue growth for the third quarter of 2020, with total revenues increasing by 12% year-over-year to $6.42 billion, driven by strong performance across several key products including Otezla, Prolia, and Repatha. Net income saw a modest increase to $2.02 billion, resulting in diluted earnings per share of $3.43. The company's balance sheet remains robust, with total assets growing to $64.6 billion and substantial cash, cash equivalents, and marketable securities totaling $12.4 billion. Amgen also continued its capital return program, repurchasing $2.3 billion in stock and paying dividends, while managing a significant debt load of approximately $34.2 billion.

Amgen Inc. reported total revenues of $6.2 billion for the second quarter of 2020, a 6% increase compared to the same period last year, driven primarily by a 9% increase in total product sales. The company's net income for the quarter was $1.8 billion, or $3.05 per diluted share, representing a decrease of 17% and 15% respectively, from the prior year. This decline in profitability was influenced by higher operating expenses, notably cost of sales which rose significantly due to the amortization of expenses related to the Otezla acquisition. Despite the decrease in net income, the company demonstrated robust operating cash flow and maintained a strong liquidity position with $11.4 billion in cash, cash equivalents, and marketable securities. The acquisition of Otezla in late 2019 continues to significantly impact the financial results, contributing to revenue growth but also increasing operating expenses. The company also experienced a decrease in sales for some of its established products like ENBREL and Neulasta due to market dynamics and biosimilar competition. However, newer products such as Repatha and Otezla, along with contributions from other products, have shown strong growth, offsetting some of these declines. Amgen continues to manage its capital effectively through dividends and share repurchases while also investing in its pipeline and strategic collaborations, notably with BeiGene for oncology products in China.

Amgen Inc. (AMGN) reported its first quarter 2020 results, showcasing a significant increase in total revenues driven by the acquisition of Otezla and growth in key products. Total revenues rose 11% year-over-year to $6.16 billion, primarily due to a 12% increase in product sales to $5.89 billion. This growth was bolstered by strong performances from Prolia®, Repatha®, and the newly acquired Otezla®, which generated $479 million in its first full quarter. However, net income saw a slight decrease of 8% to $1.83 billion, and diluted Earnings Per Share (EPS) declined by 3% to $3.07, largely impacted by increased operating expenses, particularly related to the Otezla acquisition and amortization of intangible assets. The company also highlighted its proactive capital allocation strategy, including significant share repurchases and dividend payments, while managing its debt profile. Amgen’s cash position remains robust, supporting ongoing operations and strategic investments. The company acknowledged the emerging impact of the COVID-19 pandemic, noting potential demand shifts for certain products and temporary pauses in clinical trial enrollments, while emphasizing its commitment to employee safety and business continuity. Despite the challenges posed by the pandemic, Amgen remains focused on its pipeline and strategic initiatives.

Amgen Inc. reported third-quarter 2019 results with total revenues of $5.74 billion, a decrease of 3% year-over-year, primarily due to lower other revenues. Net income rose 6% to $1.97 billion, and diluted Earnings Per Share (EPS) increased by 14% to $3.27. For the first nine months of 2019, total revenues decreased by 2% to $17.17 billion, while net income declined 5% to $6.14 billion, and diluted EPS increased by 4% to $10.01. The company announced a significant development with an agreement to acquire worldwide rights to Otezla® for $13.4 billion, expected to close by year-end 2019, which is intended to expand its inflammation portfolio. The report also highlighted ongoing legal proceedings related to patent disputes and biosimilar competition, which could materially impact financial results. Amgen continued its capital return program, repurchasing $6.6 billion of its stock in the first nine months and declaring quarterly dividends.

Amgen Inc. reported revenues of $5.87 billion for the third quarter of 2019, a decrease of 3% year-over-year, reflecting ongoing pressures from biosimilar competition, particularly impacting Neulasta® and Sensipar®/Mimpara® sales. Despite the top-line decline, the company demonstrated effective cost management, with operating expenses remaining relatively flat for the quarter. Diluted Earnings Per Share (EPS) saw a slight increase to $3.57, up 3% year-over-year, signaling operational efficiency and a strong focus on profitability. The company continued its robust capital return program, repurchasing $5.4 billion in common stock during the first six months of 2019 and increasing its authorized repurchase amount, demonstrating confidence in its future cash flows and commitment to shareholder value. The balance sheet remains solid, with total assets of $59.37 billion. While cash and cash equivalents decreased to $5.53 billion from $6.95 billion at year-end 2018, the company maintains substantial liquidity through marketable securities. Amgen is actively managing its debt, reducing long-term debt to $27.8 billion. The company's legal and regulatory landscape remains active, with ongoing patent litigations and potential impacts from pricing and reimbursement policies, which investors should monitor closely.

Amgen Inc. reported a slight decrease in total revenues for the first quarter of 2019 compared to the same period in 2018, driven by a modest decline in product sales that was offset by an increase in other revenues, primarily royalties. While total revenues remained largely flat, net income and diluted Earnings Per Share (EPS) experienced a more significant decline, indicating pressure on profitability. This was attributed to a notable increase in operating expenses, particularly in Cost of Sales and Research & Development, impacting the bottom line. The company continued its capital return program, with substantial share repurchases and dividend payments. However, these activities, alongside operating costs, contributed to a decrease in cash and cash equivalents and marketable securities. Amgen faces ongoing challenges from biosimilar competition for key products like Neulasta® and Sensipar®/Mimpara®, which are impacting sales. Despite these headwinds, the company highlighted growth in Prolia® and KYPROLIS®, and strategic advancements such as the FDA approval of EVENITY™.

Amgen Inc. reported a slight increase in total revenues for the nine months ended September 30, 2018, reaching $17.5 billion, a 3% rise from the prior year. This growth was primarily driven by product sales, which increased by 2% to $16.5 billion, with notable growth in Prolia®, XGEVA®, and 'Other products', partially offset by declines in ENBREL®, Neulasta®, Aranesp®, Sensipar®/Mimpara®, and EPOGEN®. The company's net income saw a more significant increase of 4% to $6.5 billion for the nine-month period, leading to a substantial 14% rise in diluted Earnings Per Share (EPS) to $9.61, reflecting the benefits of U.S. corporate tax reform. However, the third quarter of 2018 showed a slight dip in net income and a modest increase in diluted EPS compared to the prior year's quarter, highlighting sequential pressures. Financially, Amgen significantly strengthened its cash position, ending the period with $11.96 billion in cash and cash equivalents, a substantial increase from $3.8 billion at the end of 2017, primarily due to strong operating cash flows and strategic management of marketable securities. The company also continued its aggressive capital return strategy, repurchasing approximately $15.7 billion of its stock in the first nine months of 2018. The company is navigating patent expiries and increasing biosimilar competition for some of its key legacy products, which is reflected in sales trends for drugs like ENBREL and Neulasta®.

Amgen Inc. reported solid revenue growth in the second quarter of 2018, with total revenues increasing by 4% year-over-year to $6.06 billion. This growth was primarily driven by a 10% increase in Rest of World (ROW) product sales and a significant 61% surge in other revenues, largely due to a milestone payment from Novartis for their migraine treatment, AimovigTM. Net income saw a healthy increase of 7% to $2.30 billion, leading to diluted EPS of $3.48, up 20% compared to the prior year, demonstrating improved profitability and effective cost management. The company also executed a substantial stock repurchase program, highlighting its commitment to returning capital to shareholders and a strong cash flow position.

Amgen Inc.'s first quarter 2018 report shows robust financial performance with a notable increase in net income and diluted earnings per share compared to the prior year. Total revenues grew to $5.55 billion, driven by a 3% increase in product sales, primarily from higher unit demand, although some key products like Neulasta® and Enbrel® saw slight declines. The company also benefited from a significantly lower effective tax rate, a direct result of the U.S. Tax Cuts and Jobs Act of 2017. Operating expenses decreased, contributing to a 5% rise in operating income. Operationally, Amgen completed the acquisition of the remaining 50% of Kirin-Amgen, Inc., consolidating its operations and eliminating future royalty obligations. The company also continued its aggressive capital return program, repurchasing a substantial amount of its common stock and paying dividends. Management expressed confidence in future cash flows, supported by a strong financial position and ongoing investment in the business.

Amgen Inc. reported relatively flat total revenues for the third quarter of 2017 compared to the prior year, with a slight decrease in product sales offset by an increase in other revenues. Net income also remained stable, but diluted Earnings Per Share (EPS) saw a modest increase due to a reduction in outstanding shares. The company's balance sheet reflects a solid cash position and significant investments in marketable securities. Operating expenses showed a slight increase due to specific charges, but underlying efficiency improvements were noted. Amgen continued its capital return strategy through dividends and share repurchases, demonstrating confidence in future cash flows. The company is navigating patent litigations and biosimilar competition, while also facing operational challenges and expenses related to Hurricane Maria in Puerto Rico.

Amgen Inc. reported solid financial results for the second quarter and first half of 2017, demonstrating revenue growth and significant improvements in profitability. Total revenues for the three months ended June 30, 2017, increased by 2% to $5.81 billion, while net income saw a substantial 15% increase to $2.15 billion, translating to a diluted EPS of $2.91, up 18% from the prior year. The company's performance was driven by strong sales from key products such as Prolia®, Sensipar®/Mimpara®, Repatha®, and KYPROLIS®, which helped offset declines in established products like Enbrel® and Neulasta®. Operating expenses were well-managed, decreasing by 6% for the quarter due to efficiency improvements and the expiration of residual royalty payments. This operational efficiency contributed to a 13% increase in operating income. Amgen continues to focus on returning capital to shareholders, with significant stock repurchases and dividend payments, while maintaining a robust cash position.

Amgen Inc. reported its first-quarter 2017 financial results, showcasing solid performance with a net income of $2.07 billion, or $2.79 per diluted share, a notable increase from the prior year. Total revenues slightly declined by 1% to $5.46 billion, primarily due to a decrease in other revenues, while product sales remained largely stable. The company demonstrated effective cost management, with operating expenses down 8% year-over-year, leading to an 8% increase in operating income. Key product sales showed mixed performance, with strong growth in Prolia® (21%) and Sensipar®/Mimpara® (15%), while Enbrel® experienced a significant decline (15%) due to competition. The company continued to return capital to shareholders through dividends and stock repurchases. Amgen also highlighted significant progress in its pipeline and regulatory submissions, including an expanded indication for XGEVA® and positive cardiovascular outcomes data for Repatha®.

Amgen Inc. reported solid financial performance for the third quarter and the first nine months of 2016, demonstrating revenue growth and improved profitability. Total revenues for the nine months increased by 6% to $17.0 billion, driven by a 4% rise in product sales and a significant 56% increase in other revenues, largely attributed to milestone payments and royalty income. Net income for the nine-month period rose by 13% to $5.8 billion, translating to a 14% increase in diluted Earnings Per Share (EPS) to $7.63. This growth was supported by effective cost management, with operating expenses remaining flat year-over-year due to ongoing transformation and process improvement initiatives, which are expected to yield further cost savings. The company also continued to return capital to shareholders through substantial stock repurchases and increased dividend payments, signaling confidence in its financial health and future prospects.

Amgen Inc. reported solid financial results for the second quarter and first half of 2016, showcasing revenue and net income growth year-over-year. Total revenues increased by 6% for the quarter and 8% for the first six months, driven by strong performance in key products like Enbrel, Prolia, and Kyprolis. The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues, leading to a notable increase in operating income (15% for the quarter, 17% for the first half) and net income (13% for the quarter, 15% for the first half). Diluted Earnings Per Share (EPS) also saw a corresponding increase, indicating enhanced profitability for shareholders. Amgen continues to actively return capital to shareholders through dividends and stock repurchases, underscoring its financial health and commitment to shareholder value.

Amgen Inc. reported strong financial results for the first quarter of 2016, with total revenues increasing by 10% to $5.53 billion and net income growing by 17% to $1.90 billion. Diluted earnings per share (EPS) also saw a significant increase of 18% to $2.50. This growth was driven by a 7% increase in product sales, reaching $5.24 billion, with key products like Enbrel, Prolia, and Aranesp showing robust performance. The company also benefited from an 81% surge in other revenues, largely due to an upfront partner payment and increased royalty income. Despite a 4% increase in operating expenses, the company's operating income grew by 19%, demonstrating effective cost management and revenue expansion. Amgen continued its commitment to returning capital to shareholders, declaring a quarterly dividend and actively engaging in stock repurchases.

Amgen Inc. (AMGN) reported strong financial performance for the nine months ended September 30, 2015, demonstrating significant growth in revenues and net income compared to the prior year. Total revenues increased by 9% to $16.1 billion, primarily driven by a 10% rise in product sales to $14.2 billion. This growth was fueled by key products such as Enbrel, Neulasta, Xgeva, and Sensipar/Mimpara, which showed robust sales increases across various regions, particularly in the U.S. Profitability also saw substantial improvement, with net income rising by 33% to $5.1 billion and diluted Earnings Per Share (EPS) increasing by 33% to $6.70. This enhanced profitability is attributed to higher revenues, improved operating income, and a reduction in operating expenses, partly due to cost-saving restructuring efforts initiated in the prior year. The company also actively returned capital to shareholders through dividends and a significant stock repurchase program, signaling confidence in its financial health and future prospects.

This filing represents an amendment to Amgen Inc.'s (AMGN) Quarterly Report on Form 10-Q for the period ending June 30, 2015. The primary purpose of this amendment is to provide a corrected Exhibit 10.18, an agreement between Amgen Inc. and Jonathan Graham dated May 11, 2015. No other financial information or disclosures within the original Form 10-Q are altered by this amendment. Investors should note that this filing does not introduce new financial performance data or operational updates for the second quarter of 2015. The original Form 10-Q, filed on August 5, 2015, would contain the substantive financial and operational details. This amendment focuses solely on the correction of a specific exhibit, ensuring the completeness and accuracy of the SEC filing record.

Amgen Inc.'s second-quarter 2015 report shows solid revenue growth, with total revenues reaching $5.37 billion, a 4% increase year-over-year, primarily driven by strong product sales, up 6% to $5.23 billion. This growth was fueled by key products like ENBREL, Prolia®, Sensipar®, and Kyprolis®. Net income also saw a healthy increase of 7% to $1.65 billion, translating to a diluted Earnings Per Share (EPS) of $2.15, up 7% from the prior year. The company continues to invest in its pipeline, with R&D expenses decreasing slightly for the quarter but still representing a significant portion of overall expenses. Financially, Amgen maintains a strong balance sheet with total assets of $71.2 billion and robust liquidity, evidenced by cash and cash equivalents and marketable securities totaling $30.0 billion. The company has also been actively returning capital to shareholders through dividends and share repurchases, with $2.9 billion remaining available under its stock repurchase program. While the company faces ongoing legal and regulatory challenges, including biosimilar competition and patent expirations for older drugs like Neulasta® and EPOGEN®, the diversified product portfolio and ongoing pipeline development for new therapies like Repatha™ appear to position Amgen for continued growth.

Amgen Inc. reported strong financial results for the first quarter of 2015, demonstrating robust revenue growth and significant improvements in profitability. Total revenues increased by 11% year-over-year, reaching $5.03 billion, primarily driven by a 12% rise in product sales to $4.87 billion. This growth was fueled by strong performance across key products such as Enbrel, Prolia, XGEVA, Sensipar/Mimpara, and Epogen. Profitability saw a substantial jump, with operating income increasing by 48% to $2.02 billion and net income growing by 51% to $1.62 billion. This improved profitability is attributed to a decrease in operating expenses, largely due to the company's ongoing restructuring plan which aims to enhance efficiency and reduce costs, alongside favorable changes in the cost of sales as a percentage of revenue. Diluted Earnings Per Share (EPS) also surged by 51% to $2.11. The company continued to return capital to shareholders through dividends and share repurchases, underscoring its financial strength and commitment to shareholder value.

Amgen Inc.'s third quarter 2014 report shows mixed results for investors. While total revenues increased by 6% year-over-year to $5.03 billion, driven by strong performance in "Other revenues" and growth in key products like XGEVA® and Prolia®, net income declined by 9% to $1.24 billion. This decline is primarily attributable to a significant increase in operating expenses, notably cost of sales and restructuring charges, impacting profitability. The company has initiated a substantial restructuring plan, aiming to reduce its workforce and facility footprint, which resulted in $376 million in charges during the quarter. Despite these cost pressures and a decrease in earnings per share (EPS) to $1.61 from $1.79 in the prior year period, Amgen continues to return capital to shareholders through consistent dividend payments. The balance sheet remains robust, with total assets increasing to $70.8 billion, supported by substantial marketable securities and cash reserves.

Amgen Inc. reported solid revenue growth for the second quarter of 2014, with total revenues reaching $5.18 billion, an 11% increase compared to the prior year quarter. This growth was primarily driven by strong performance in product sales, particularly from newer products like Kyprolis® (acquired through Onyx Pharmaceuticals) and continued strength in established blockbusters such as Enbrel®, Prolia®, and Xgeva®. Despite increased operating expenses, largely due to acquisition-related costs including amortization of intangible assets from the Onyx acquisition, operating income saw a significant 23% increase. Net income also rose by 23% year-over-year for the quarter, signaling effective cost management and operational efficiency. The company also announced a significant restructuring plan in July 2014, involving workforce reductions and facility closures to further optimize its cost structure, which is expected to incur substantial charges but aims to drive future innovation and efficiency.

Amgen Inc.'s first quarter 2014 report shows a mixed financial performance. Total revenues increased by 7% year-over-year to $4.52 billion, driven by a 5% rise in product sales and a significant 90% surge in other revenues, largely due to the Onyx Pharmaceuticals acquisition. However, net income saw a substantial decrease of 25% to $1.07 billion, and diluted Earnings Per Share (EPS) fell by 26% to $1.40. This decline in profitability is primarily attributed to favorable tax items in the prior year's quarter and increased operating expenses, particularly in Cost of Sales, which rose significantly due to amortization of acquired intangible assets from the Onyx acquisition and a charge related to the termination of a supply contract. The company's balance sheet remains robust, with total assets growing to $67.0 billion. While cash and cash equivalents decreased slightly, marketable securities increased, contributing to a rise in total cash, cash equivalents, and marketable securities. Long-term debt remained largely stable. The company continues its commitment to returning capital to shareholders through dividends, declaring a quarterly dividend of $0.61 per share. While stock repurchases were minimal in the period, a substantial $1.6 billion remains authorized under the company's repurchase program.

Amgen Inc. reported solid financial performance for the third quarter of 2013, demonstrating robust revenue and net income growth compared to the prior year. Total revenues increased by 10% year-over-year to $4.75 billion, driven primarily by strong product sales, particularly from key brands like Neulasta/Neupogen, Enbrel, Xgeva, and Prolia. Net income saw a significant jump of 24% to $1.37 billion, resulting in diluted Earnings Per Share (EPS) of $1.79, up from $1.41 in the same period last year. The company highlighted its ongoing strategic initiatives, including continued investment in research and development and the significant acquisition of Onyx Pharmaceuticals completed in early October 2013 for approximately $9.7 billion. This acquisition is expected to bolster Amgen's oncology franchise. Amgen also continues to return capital to shareholders through dividends and has a substantial repurchase program in place, although no shares were repurchased in the second or third quarters of 2013. The company maintains a strong liquidity position, with substantial cash and marketable securities, though it has also increased its long-term debt to finance strategic initiatives.

Amgen Inc. reported solid financial results for the second quarter and first half of 2013, demonstrating continued revenue growth driven by key products like Neulasta®, Enbrel®, XGEVA®, and Prolia®. While overall revenues saw a modest increase, net income experienced a slight decrease in the quarter but a significant increase year-to-date, largely due to favorable tax benefits and a lower effective tax rate resulting from the reinstatement of the R&D tax credit and settlement of IRS examinations. The company's financial position remains strong, with substantial cash, cash equivalents, and marketable securities, though long-term debt is also significant. Amgen continued to return capital to shareholders through dividends and share repurchases, with a substantial amount remaining under its stock repurchase program. Key operational developments included the positive Phase 3 trial results for trebananib in ovarian cancer and FDA approval for XGEVA® in giant cell tumor of bone. The company also provided updates on its pipeline, including AMG 145 and talimogene laherparepvec, and noted a temporary suspension in enrollment for a biosimilar Herceptin® study. The company remains focused on advancing its therapeutic pipeline while managing operational expenses and regulatory complexities.

Amgen Inc. reported solid financial results for the first quarter of 2013, demonstrating revenue growth and improved profitability. Total revenues increased by 5% year-over-year to $4.24 billion, driven primarily by a 6% increase in product sales, notably strong performance from Enbrel, Xgeva, and Prolia. Net income saw a significant jump of 21% to $1.43 billion, with diluted Earnings Per Share (EPS) rising by 27% to $1.88. This improved profitability was bolstered by a lower effective income tax rate, largely due to a favorable settlement with the IRS and the retroactive reinstatement of the federal R&D tax credit. The company maintained a strong liquidity position with $21.3 billion in cash, cash equivalents, and marketable securities, although total debt remained substantial at $23.9 billion. Amgen continued its commitment to returning capital to shareholders through robust share repurchases, totaling $771 million in the quarter, and a consistent quarterly dividend. The company also highlighted progress in its product pipeline, including positive Phase 3 results for talimogene laherparepvec in melanoma and the initiation of Phase 3 studies for AMG 416.

Amgen Inc. reported strong financial results for the nine months ended September 30, 2012, demonstrating significant growth in both revenues and net income compared to the same period in 2011. Total revenues increased by 11% to $12.84 billion, primarily driven by a robust 8% rise in product sales to $12.30 billion, with notable performance from key products like ENBREL and Neulasta®/NEUPOGEN®. The company successfully executed strategic business combinations, acquiring Micromet, Inc., Mustafa Nevzat Pharmaceuticals, and KAI Pharmaceuticals, which contributed to a substantial increase in goodwill and intangible assets. This expansion reflects Amgen's commitment to strengthening its pipeline and market presence in oncology, Turkey, and nephrology. Despite increased investments in research and development and higher interest expenses, Amgen maintained strong operational efficiency, leading to a 43% increase in operating income and a 29% rise in net income to $3.56 billion for the nine-month period. Amgen also demonstrated a strong commitment to returning capital to shareholders through significant stock repurchases and consistent dividend payments. The company's financial position remains robust, with substantial cash and marketable securities, enabling continued investment in growth opportunities and shareholder returns.

Amgen Inc. reported solid financial results for the second quarter and first half of 2012, demonstrating revenue growth driven by key products like Enbrel, Neulasta/Neupogen, and a notable increase in "Other products." Total revenues for the quarter rose 13% year-over-year to $4.48 billion, with net income up 8% to $1.27 billion. Diluted EPS saw a significant 29% increase to $1.61, largely due to a reduced share count from aggressive share repurchases. The company also announced the strategic acquisitions of Micromet, Inc. and Mustafa Nevzat Pharmaceuticals, bolstering its oncology and Turkish market presence, respectively. Despite facing patent expirations on some principal products, Amgen's financial strength is evident in its robust operating cash flow and significant cash reserves, positioning it for continued investment in innovation and return of capital to shareholders.

Amgen Inc. reported solid financial results for the first quarter of 2012, demonstrating revenue growth and improved profitability. Total revenues increased by 9% year-over-year to $4.05 billion, driven by an 8% rise in product sales, primarily from key products like Neulasta®/NEUPOGEN® and ENBREL®. Operating income saw a significant 14% increase, leading to a 5% rise in net income to $1.18 billion. Diluted Earnings Per Share (EPS) also showed strong growth, increasing by 23% to $1.48, largely due to the company's effective stock repurchase program which reduced the share count. Strategically, Amgen made a significant move by acquiring Micromet, Inc. in March 2012 to bolster its oncology pipeline, and also entered into a key collaboration with AstraZeneca for the development of monoclonal antibodies in inflammation. While the company faces ongoing challenges such as the decline in sales for its erythropoiesis-stimulating agents (ESAs) like Aranesp® and EPOGEN®, and the increasing cost of sales due to the Puerto Rico excise tax, the overall performance indicates a resilient business with a focused approach on strategic growth and innovation.

Amgen Inc. filed an amendment to its Form 10-Q for the quarterly period ended September 30, 2011. This amendment primarily addresses the re-filing of Exhibit 10.47, an amendment to a Master Services Agreement with International Business Machines Corporation, after discussions with the SEC regarding confidential treatment. The company has provided a revised version of the exhibit with less redaction and included its schedules and exhibits. For investors, this filing does not introduce new financial results or operational updates for the period. Its significance lies in the procedural correction and the updated disclosure of material contractual information related to Amgen's IT services. Investors should refer to the original 10-Q filing from November 4, 2011, for the company's financial performance and operational highlights for the September 30, 2011 quarter.

Amgen Inc.'s third quarter 2011 results showed a significant decrease in net income, primarily driven by a $780 million legal settlement charge related to sales and marketing practices. Despite this, total revenues grew 3% year-over-year to $3.94 billion, with product sales increasing 3% to $3.88 billion, largely supported by strong performance in Neulasta®/NEUPOGEN® and ENBREL, which offset declines in EPOGEN® and Aranesp®. The company demonstrated solid cash flow generation, with $3.54 billion in cash from operations for the nine-month period. Amgen continued its commitment to returning capital to shareholders, with $3.15 billion in share repurchases and the initiation of a quarterly dividend. The company also made strategic acquisitions, including BioVex Group, Inc., to bolster its pipeline, particularly in oncology. Looking ahead, Amgen faces ongoing challenges from the decline in its erythropoiesis-stimulating agents (ESAs) and potential impacts from healthcare reform and evolving global economic conditions. However, the company's strategic investments in R&D and recent product launches like XGEVA® and Prolia® indicate a focus on future growth drivers.

Amgen Inc.'s (AMGN) second-quarter 2011 filing for the period ending June 29, 2011, indicates a mixed financial performance. While the company provided detailed financial statements and management's discussion on its results of operations, the filing does not immediately reveal significant year-over-year growth or decline in top-line revenue or profitability without specific figures. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) section for a deeper understanding of the operational drivers, including product sales performance, cost management, and any new developments impacting financial condition. Key areas to scrutinize in the MD&A would include revenue trends for Amgen's key drugs, such as Enbrel, Aranesp, and Neulasta, as well as the impact of any litigation or regulatory challenges, which are mentioned in Part II of the filing. The company's liquidity and capital resources, along with any off-balance sheet arrangements or contingent liabilities, will also be crucial for assessing the company's financial health and future prospects. The filing also touches upon market risk and controls and procedures, providing further context for investors.

Amgen Inc. (AMGN) reported its first quarter results for the period ending March 30, 2011. The company appears to be in a stable financial position based on the structure of the 10-Q filing, which includes its condensed consolidated financial statements (income, balance sheet, and cash flows) and the critical Management's Discussion and Analysis (MD&A). Investors should pay close attention to the MD&A for insights into the company's operational performance, financial condition, and future outlook. Key areas of focus for investors in this filing would include revenue generation and profitability trends, cash flow from operations, and any significant developments or risks disclosed. The inclusion of Legal Proceedings and Risk Factors sections indicates potential areas of concern or areas requiring further due diligence by investors. Without the specific financial data from the statements, a detailed quantitative analysis is not possible, but the filing structure suggests a comprehensive review of the company's performance and risks is available.

Amgen Inc. reported steady revenue growth for the nine months ended September 30, 2010, with total revenues increasing by 3% to $11.212 billion compared to the same period in 2009. While total revenues remained flat year-over-year for the third quarter, the company demonstrated strong operational performance. Net income for the nine-month period saw a slight decrease of 2% to $3.605 billion, primarily impacted by a higher effective tax rate. Diluted Earnings Per Share (EPS) for the nine months increased by 4% to $3.71, benefiting from a reduced share count due to active stock repurchases. The company's balance sheet shows a healthy financial position with total assets of $43.534 billion and total stockholders' equity of $24.071 billion as of September 30, 2010. Cash and cash equivalents, along with marketable securities, stood at $17.049 billion, providing ample liquidity. Amgen continued to return value to shareholders through its stock repurchase program, with $2.7 billion spent on repurchases during the first nine months of 2010.

Amgen Inc. (AMGN) reported its financial results for the second quarter ended June 29, 2010. The company demonstrated solid performance with continued revenue generation and active management of its operating expenses. Investors should note the company's ongoing focus on product sales and the management of its research and development pipeline. While specific figures for revenue and net income are detailed within the filing, the overall trend suggests a company navigating a dynamic pharmaceutical landscape. The Management's Discussion and Analysis section is crucial for understanding the drivers behind the financial performance, including any impacts from product sales, pipeline advancements, and strategic initiatives. Investors should pay close attention to the discussion on liquidity, capital resources, and any significant legal proceedings or risk factors that could influence future operations and financial health.

Amgen Inc. reported strong financial results for the first quarter of 2010, with total revenues reaching $3.59 billion, a 8.5% increase year-over-year. Net income also saw a healthy rise to $1.17 billion, translating to diluted earnings per share of $1.18, up from $0.98 in the prior year's quarter. This growth was primarily driven by a 9% increase in product sales, reaching $3.53 billion, fueled by strong performance across key products like EPOGEN, Neulasta/NEUPOGEN, and ENBREL, as well as significant international growth. The company maintained a robust balance sheet with $14.1 billion in cash, cash equivalents, and marketable securities. However, total debt increased due to new note issuances and the current portion of convertible notes. Amgen continued its commitment to returning capital to shareholders through a significant stock repurchase program, repurchasing approximately 29 million shares in the quarter. Despite positive financial performance, the company highlighted the potential adverse impacts of the recently enacted U.S. healthcare reform law, which is expected to significantly affect future revenue and operations.